Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

KOL Investor Event on Iron Deficiency

Innovation in Iron Deficiency Treatment with a Focus on Clinical Utility of Accrufer®/Feraccru®

Webinar on Thursday 10 February at 10am EST / 3pm GMT

LONDON, UK - 4 February 2022 - Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®(ferric maltol), announces it will host a Key Opinion Leader ("KOL") event for Investors on "Iron Deficiency Treatment Innovation" with a focus on clinical utility of Accrufer®/Feraccru® on Thursday 10 February 2022 at 10am (EST) / 3pm (GMT).

The live webinar will feature presentations from:

·   Dr. Lee P. Shulman MD FACMG FACOG (Professor of Obstetrics and Gynecology at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois), who will discuss the current treatment landscape and unmet medical need in treating patients with iron deficiency.

·    Dr. Carsten Schmidt, MA, FEBGH (Director of Medical Clinic II - Gastroenterology, Hepatology, Endocrinology, Diabetology and Infectious Diseases - Fulda Hospital, Marburg University Medicine), who will discuss Shield Therapeutics' potential treatment solution Accrufer®, a stable non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Additionally, members of the Shield senior management team will also be in attendance.

Registration for this event is available through LifeSci Events. A live video webcast will be available in the "Events" section of the Shield corporate website. An archived version of the event will be available on the website for 60 days.

For speaker biographies please visit the website here: https://www.shieldtherapeutics.com/events/  

For further information please contact:

About Accrufer®/Feraccru®

Shield's lead product Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer® in the US and Feraccru® is already being commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

For more information, please visit www.shieldtherapeutics.com or follow Shield on Twitter @ShieldTx.